M&G Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

M&G Investment Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34,103	Closed	-$512	–	756
2021 Q3	$512	Hold	34,103	–	–	﹤0.01%	676
2021 Q2	$648	Buy	+34,103	New	+$629K	﹤0.01%	663

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

M&G Investment Management's XENE Position: Q4 2021 in Review

M&G Investment Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 34,103 shares — an estimated $512 sold.

M&G Investment Management first reported a position in XENE in Q2 2021 and held it in 2 quarters. The position peaked at $648 in Q2 2021. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

M&G Investment Management reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
M&G Investment Management sold 34,103 Xenon Pharmaceuticals shares in Q4 2021, an estimated $512.
M&G Investment Management first reported a position in Xenon Pharmaceuticals in Q2 2021 and held it in 2 quarters.
M&G Investment Management's Xenon Pharmaceuticals position peaked at $648 in Q2 2021.
130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.